EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Repurposing incretin therapies: a narrative review of emerging indications across cardiometabolic, liver, kidney, neurological, psychiatric, and other systems

Ibrahim S Alhomoud iD, Sarah E Wheeler iD, Dave L Dixon iD

Canadian Journal of Physiology and Pharmacology · 2025

DOI: 10.1139/cjpp-2025-0038 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Canadian Journal of Physiology and Pharmacology, 2025. Verfasst von Ibrahim S Alhomoud und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Practice, College of Pharmacy, Qassim University, Qassim 51452, Saudi Arabia. Hauptthemen laut MEDLINE: Incretins, Drug Repositioning. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 117 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Incretin therapies have revolutionized the management of type 2 diabetes and obesity. Recent evidence suggests that these agents modulate key pathways involved in cardiovascular, renal, hepatic, neuropsychiatric, and reproductive health. In this narrative review, we examine the role of incretin-based therapies in chronic kidney disease, heart failure with preserved ejection fraction, metabolic dysfunction-associated steatotic liver disease, neurodegenerative and cognitive disorders, substance use disorder, obstructive sleep apnea, knee osteoarthritis, and polycystic ovary syndrome. The mechanisms underlying these benefits appear to extend beyond glucose and weight regulation, including anti-inflammatory, neuroprotective, and cardiorenal effects. We summarize key clinical trial data, highlight knowledge gaps, and discuss future directions for integrating incretin-based therapies into broader clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

IncretinsDrug RepositioningHumansAnimalsDiabetes Mellitus, Type 2Mental DisordersLiverKidney

Stichwörter der Autor:innen

cardiometabolic diseaseincretin therapiesmetabolic dysfunction-associated steatotic liver disease (MASLD)neurodegenerative disordersobstructive sleep apneasubstance use disorder

Substanzen

Incretins

Autor:innen und Institutionen

  • Department of Pharmacy Practice, College of Pharmacy, Qassim University, Qassim 51452, Saudi Arabia.
  • Department of Pharmacotherapy & Outcomes Science, Virginia Commonwealth University School of Pharmacy, Richmond, VA, USA.

ORCID-Profile: Ibrahim S Alhomoud, Sarah E Wheeler, Dave L Dixon

Zitieren

APA

Alhomoud, I. S., Wheeler, S., & Dixon, D. (2025). Repurposing incretin therapies: a narrative review of emerging indications across cardiometabolic, liver, kidney, neurological, psychiatric, and other systems. Canadian Journal of Physiology and Pharmacology. https://doi.org/10.1139/cjpp-2025-0038

Vancouver

Alhomoud IS, Wheeler S, Dixon D. Repurposing incretin therapies: a narrative review of emerging indications across cardiometabolic, liver, kidney, neurological, psychiatric, and other systems. Canadian Journal of Physiology and Pharmacology. 2025. doi:10.1139/cjpp-2025-0038

BibTeX
@article{Alhomoud2025,
  author = {Alhomoud, Ibrahim S and Wheeler, Sarah E and Dixon, Dave L},
  title = {Repurposing incretin therapies: a narrative review of emerging indications across cardiometabolic, liver, kidney, neurological, psychiatric, and other systems},
  journal = {Canadian Journal of Physiology and Pharmacology},
  year = {2025},
  doi = {10.1139/cjpp-2025-0038}
}
Kostenlos starten →